These findings help decipher and define optimal targets within the promotor region of FXN, and provide evidence for the viral delivery of endogenous FXN sequences to restore frataxin expression as a potential gene therapy approach for FRDA. The gene discussed is FXN; the disease is Friedreich ataxia.